CRIS Current Research Information System

TREVISANI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.000
AS - Asia 9.787
EU - Europa 9.727
SA - Sud America 739
AF - Africa 704
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 9
Totale 34.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.917
SG - Singapore 3.086
CN - Cina 2.676
GB - Regno Unito 2.473
VN - Vietnam 1.933
IT - Italia 1.687
DE - Germania 1.257
SE - Svezia 1.065
HK - Hong Kong 815
IN - India 615
RU - Federazione Russa 564
UA - Ucraina 545
BR - Brasile 537
FR - Francia 431
IE - Irlanda 415
NL - Olanda 309
CH - Svizzera 262
TG - Togo 227
ZA - Sudafrica 216
EE - Estonia 193
KR - Corea 186
FI - Finlandia 155
JP - Giappone 143
CI - Costa d'Avorio 120
JO - Giordania 93
BG - Bulgaria 92
AR - Argentina 89
SC - Seychelles 74
ID - Indonesia 57
AT - Austria 56
CA - Canada 45
EC - Ecuador 39
ES - Italia 36
BE - Belgio 34
IR - Iran 33
PL - Polonia 32
GR - Grecia 27
MX - Messico 26
NG - Nigeria 23
BD - Bangladesh 20
CL - Cile 20
CO - Colombia 19
HR - Croazia 18
UZ - Uzbekistan 18
AU - Australia 17
TR - Turchia 17
LB - Libano 13
LT - Lituania 13
PH - Filippine 13
PK - Pakistan 13
PY - Paraguay 13
CZ - Repubblica Ceca 12
EG - Egitto 11
MA - Marocco 11
RO - Romania 11
IQ - Iraq 10
PE - Perù 8
AE - Emirati Arabi Uniti 7
DK - Danimarca 7
MY - Malesia 7
TW - Taiwan 7
VE - Venezuela 7
PT - Portogallo 6
EU - Europa 5
LU - Lussemburgo 5
MK - Macedonia 5
SV - El Salvador 5
KZ - Kazakistan 4
SA - Arabia Saudita 4
TH - Thailandia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
DZ - Algeria 3
NZ - Nuova Zelanda 3
OM - Oman 3
TN - Tunisia 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
BH - Bahrain 2
CM - Camerun 2
ET - Etiopia 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
LV - Lettonia 2
MD - Moldavia 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BZ - Belize 1
CG - Congo 1
CV - Capo Verde 1
GE - Georgia 1
GN - Guinea 1
HN - Honduras 1
HT - Haiti 1
IM - Isola di Man 1
Totale 34.973
Salva come PNG Salva come JPEG
Città #
Southend 2.169
Singapore 1.920
Fairfield 1.735
Ashburn 1.342
Chandler 1.112
Hong Kong 808
Woodbridge 756
Seattle 660
Santa Clara 655
Houston 649
Wilmington 649
Princeton 558
Cambridge 543
Dong Ket 540
Hefei 460
Dublin 414
Boardman 392
Bologna 382
Ho Chi Minh City 379
Ann Arbor 364
Jacksonville 359
Beijing 345
Hanoi 315
Bern 238
Westminster 228
Lomé 227
Los Angeles 222
Nanjing 215
Padova 199
Seoul 178
Berlin 161
Dallas 146
Tokyo 133
Abidjan 120
Milan 118
Buffalo 117
Saint Petersburg 105
Helsinki 103
New York 103
Shenyang 100
Jinan 96
Amman 93
San Diego 93
Sofia 90
Munich 89
Florence 81
Medford 79
Changsha 78
Redondo Beach 78
Hebei 75
Nanchang 71
Turin 71
Mülheim 68
Redmond 67
Dearborn 65
Rome 59
São Paulo 56
Tianjin 54
Haiphong 50
Bengaluru 48
Frankfurt am Main 48
London 47
Redwood City 47
Chicago 44
Bremen 43
Des Moines 43
Hangzhou 42
Zhengzhou 42
Shanghai 40
Falls Church 38
Mahé 38
Norwalk 38
Olalla 38
Nuremberg 37
Da Nang 35
Guangzhou 34
Jiaxing 34
Falkenstein 33
Brussels 32
Mountain View 32
Turku 30
Bühl 27
Phoenix 27
Kunming 26
Ningbo 26
Quận Bình Thạnh 26
Verona 25
Biên Hòa 24
Brooklyn 24
Paris 24
Ninh Bình 23
Orem 23
Vienna 23
Abeokuta 22
Jakarta 22
Düsseldorf 21
Lappeenranta 21
The Dalles 21
Pune 20
Fuzhou 19
Totale 22.939
Salva come PNG Salva come JPEG
Nome #
TACE treatment in hepatocellular carcinoma: what should we do now? 323
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 288
g-hydroxybutyrate as a treatment for alcoholism. 246
Alcol, sindrome feto-alcolica, apparato ematopoietico, muscolo-scheletrico, respiratorio, cute e reni. 237
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 236
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 233
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 229
A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. 213
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 207
Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation. 203
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 202
C-11 Acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. 200
The nutritional status modulates preservation-reperfusion injury in rat fatty liver. 198
A novel sodium overload test predicting ascites decompensation in rats with CCL4-induced cirrhosis. 198
Art in hospital: its impact on the feelings and emotional state of patients admitted to an Internal Medicine Unit. 196
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma 194
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 192
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 191
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 190
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 190
Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. 185
Monofocal hepatocellular carcinoma: How much does size matter? 185
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 184
The reduced tolerance of rat fatty liver to ischemia-reperfusion is associated to mitochondrial oxidative injury. 183
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 180
Cardiac electrophysiological abnormalities in patients with cirrhosis. 179
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 179
Long-term beta-blockade shortens Qt interval prolongation in patients with liver cirrhosis 178
Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. 178
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 178
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 178
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 176
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 174
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 174
Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischemia-reperfusion injury complicated by endotoxemia. 171
Recent advances in the natural history of hepatocellular carcinoma. 171
Gamma-hydroxybutyric acid plus naltrexone in the treatment of alcoholics resistant to monotherapy. 170
Insufficienza epatica acuta ed epatite subacuta. 167
C-type natriuretic peptide (CNP) favours natriuresis in pre-ascitic cirrhotic patients. 166
Daily profile of circulating c-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects. Relationship with renal function. 166
Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-foetoprotein levels 166
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 166
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 165
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 165
null 164
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 164
Retrospective analysis of dose–response for HCC lesions treated with 90Y resin microspheres. 163
Metabolic disorders across hepatocellular carcinoma in Italy 162
Alcohol misuse and traffic accidents 160
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group 160
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. 159
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 159
Basi scientifiche per la definizione delle linee guida in ambito clinico per l’epatocarcinoma. 158
Alfa-fetoprotein in hepatocellular carcinoma (HCC): diagnostic and prognostic role, clinical and biological predictors. Analysis of 1099 patients. 158
Differential diagnosis between focal nodular hyperplasia and hepatocellular adenoma: Potential role of double tracer PET with 11C-Acetate and 18F-FDG 158
Pattern of macrovascular invasion in hepatocellular carcinoma 158
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 158
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 157
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 157
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. 156
Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma 156
Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. 156
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 155
Adequate Interval For Hepatocellular Carcinoma Surveillance 155
Telangiectasia as a presenting sign of Graves’ disease. 155
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 155
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study 154
Hepatic decompensation is the major driver of death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. 154
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 154
Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 153
Alcolismo 153
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 153
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 149
Storia naturale dell’epatocarcinoma. 149
Trattamento farmacologico della intossicazione acuta, sindrome post-sbornia e sindrome d’astinenza da alcol. 149
What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? 149
QT Interval Correction in Patients with Cirrhosis 149
Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome 149
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 149
Portal vein arterialization increases liver regeneration in acute liver failure induced by extended hepatectomy or toxin administration in the rat 147
Hyperkeratosis of nipple skin during sorafenib treatment 147
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. 146
Gamma-hydroxy-butirric acid plus naltrexone in the treatment of alcoholics resistent to monotheraphy. 145
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 145
Torsade de pointes” during amiodarone infusion in cirrhotic woman with the prolonged QT interval. 144
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 143
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma 143
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 142
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 142
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 142
Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis 140
Retrospective analysis of dose-response for HCC lesions treated with 90Y resin microspheres. 140
Prognostication of the outcome of hepatocellular carcinoma: how to rely on science instead of the art of Nostradamus 139
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma 139
Long-term beta-blockade shortens QT interval prolongation in patients with liver cirrhosis 138
Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal. 137
Alcol ed apparato gastro-enterico. 137
Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma? 136
Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 135
Trattamento dell’epatopatia alcolica 135
Totale 16.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.895
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.895
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.129 0 0 0 0 0 155 99 176 293 204 164 1.038
2021/20224.643 307 168 267 345 431 244 104 323 197 251 1.273 733
2022/20235.089 511 758 265 597 330 363 178 259 903 125 416 384
2023/20241.571 104 239 113 133 148 283 115 102 111 102 60 61
2024/20255.822 183 904 518 395 1.009 302 385 152 81 428 231 1.234
2025/20266.667 1.425 1.073 1.240 1.040 1.474 415 0 0 0 0 0 0
Totale 35.601